Related references
Note: Only part of the references are listed.FC052: Atrasentan for the Treatment of IGA Nephropathy: Interim Results from the Affinity Study
Sung-Gyun Kim et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2022)
Effects of the Dual Endothelin Receptor Antagonist Aprocitentan on Body Weight and Fluid Homeostasis in Healthy Subjects on a High Sodium Diet
Pierre Gueneau de Mussy et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)
Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA
Alberto Ortiz et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2021)
New insights from SONAR indicate adding sodium glucose co-transporter 2 inhibitors to an endothelin receptor antagonist mitigates fluid retention and enhances albuminuria reduction
Hiddo J. L. Heerspink et al.
KIDNEY INTERNATIONAL (2021)
Randomized Dose-Response Study of the New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension
Pierre Verweij et al.
HYPERTENSION (2020)
Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017
Boris Bikbov et al.
LANCET (2020)
Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment
Ian H. de Boer et al.
KIDNEY INTERNATIONAL (2020)
Dapagliflozin in Patients with Chronic Kidney Disease
Hiddo J. L. Heerspink et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
George L. Bakris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Study Design of the Phase 3 Sparsentan Versus Irbesartan (DUPLEX) Study in Patients With Focal Segmental Glomerulosclerosis
Radko Komers et al.
KIDNEY INTERNATIONAL REPORTS (2020)
Single-and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects
Patricia N. Sidharta et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2019)
Endothelin receptor-A mediates degradation of the glomerular endothelial surface layer via pathologic crosstalk between activated podocytes and glomerular endothelial cells
Kerstin Ebefors et al.
KIDNEY INTERNATIONAL (2019)
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial
Hiddo J. L. Heerspink et al.
LANCET (2019)
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
V. Perkovic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Single-Dose Pharmacokinetics and Tolerability of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Subjects with Severe Renal Function Impairment
Patricia N. Sidharta et al.
CLINICAL DRUG INVESTIGATION (2019)
DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS
Howard Trachtman et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2018)
Endothelin ETA Receptor Blockade, by Activating ETB Receptors, Increases Vascular Permeability and Induces Exaggerated Fluid Retentions
Magali Vercauteren et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2017)
Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015
Haidong Wang et al.
LANCET (2016)
Endothelin and the Glomerulus in Chronic Kidney Disease
Matthias Barton et al.
SEMINARS IN NEPHROLOGY (2015)
Predictors of Congestive Heart Failure after Treatment with an Endothelin Receptor Antagonist
Jamo Hoekman et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2014)
Direct Action of Endothelin-1 on Podocytes Promotes Diabetic Glomerulosclerosis
Olivia Lenoir et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2014)
The Endothelin Antagonist Atrasentan Lowers Residual Albuminuria in Patients with Type 2 Diabetic Nephropathy
Dick de Zeeuw et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2014)
Endothelin and endothelin antagonists in chronic kidney disease
Donald E. Kohan et al.
KIDNEY INTERNATIONAL (2014)
Role of collecting duct endothelin in control of renal function and blood pressure
Donald E. Kohan
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2013)
Tezosentan and Right Ventricular Failure in Patients With Pulmonary Hypertension Undergoing Cardiac Surgery: The TACTICS Trial
Andre Y. Denault et al.
JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA (2013)
BUILD-3: A Randomized, Controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis
Talmadge E. King et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2011)
Absolute bioavailability and pharmacokinetics of avosentan in man
W. Dieterle et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2011)
Pharmacokinetic and tolerability profile of once-daily zibotentan (ZD4054) in Japanese and Caucasian patients with hormone-resistant prostate cancer
M. Ranson et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2011)
Randomized, Prospective, Placebo-Controlled Trial of Bosentan in Interstitial Lung Disease Secondary to Systemic Sclerosis
J. R. Seibold et al.
ARTHRITIS AND RHEUMATISM (2010)
The effects of sitaxentan on sildenafil pharmacokinetics and pharmacodynamics in healthy subjects
Fiona Stavros et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Long-Term Administration of Endothelin Receptor Antagonist Improves Coronary Endothelial Function in Patients With Early Atherosclerosis
Martin Reriani et al.
CIRCULATION (2010)
Avosentan for Overt Diabetic Nephropathy
Johannes F. E. Mann et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2010)
Avosentan Reduces Albumin Excretion in Diabetics with Macroalbuminuria
Rene R. Wenzel et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2009)
A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial
Michael A. Weber et al.
LANCET (2009)
Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes
Elena Gagliardini et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2009)
Efficacy and safety of darusentan: A novel endothelin receptor antagonist
Benjamin J. Epstein
ANNALS OF PHARMACOTHERAPY (2008)
Endothelin-1 levels and albuminuria in patients with type 2 diabetes mellitus
Claudete M. Zanatta et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2008)
A randomised, controlled trial of bosentan in severe COPD
D. Stolz et al.
EUROPEAN RESPIRATORY JOURNAL (2008)
Preeclamptic sera induce nephrin shedding from podocytes through endothelin-1 release by endothelial glomerular cells
Federica Collino et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2008)
Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure - The VERITAS Randomized controlled trials
John J. V. McMurray et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Selective and mixed endothelin receptor antagonism in cardiovascular disease
Neeraj Dhaun et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2007)
The importance of endothelin-1 for vascular dysfunction in cardiovascular disease
Felix Boehm et al.
CARDIOVASCULAR RESEARCH (2007)
Sitaxentan - In pulmonary arterial hypertension
Lesley J. Scott
DRUGS (2007)
Shigatoxin-induced endothelin-1 expression in cultured podocytes autocrinally mediates actin remodeling
Marina Morigi et al.
AMERICAN JOURNAL OF PATHOLOGY (2006)
Late-onset endothelin-A receptor blockade reduces podocyte injury in homozygous Ren-2 rats despite severe hypertension
Martin Opocensky et al.
HYPERTENSION (2006)
The endothelin system and its antagonism in chronic kidney disease
Neeraj Dhaun et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2006)
ETA and ETB receptors differentially modulate afferent and efferent arteriolar responses to endothelin
EW Inscho et al.
BRITISH JOURNAL OF PHARMACOLOGY (2005)
Cell cycle signaling by endothelin-1 requires Src nonreceptor protein tyrosine kinase
R Mishra et al.
MOLECULAR PHARMACOLOGY (2005)
In response to protein load podocytes reorganize cytoskeleton and modulate endothelin-1 gene - Implication for permselective dysfunction of chronic nephropathies
M Morigi et al.
AMERICAN JOURNAL OF PATHOLOGY (2005)
Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure - A comparison of selective and combined endothelin receptor blockade
J Goddard et al.
CIRCULATION (2004)
Role of podocytes for reversal of glomerulosclerosis and proteinuria in the aging kidney after endothelin inhibition
J Ortmann et al.
HYPERTENSION (2004)
Dual effects of endothelin-1 (1-31): Induction of mesangial cell migration and facilitation of monocyte recruitment through monocyte chemoattractant protein-1 production by mesangial cells
K Ishizawa et al.
HYPERTENSION RESEARCH (2004)
Endothelin-1 regulates arterial pulse wave velocity in vivo
CM McEniery et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2003)
Tezosentan in patients' with acute heart failure and acute coronary syndromes - Results of the randomized intravenous tezosentan study (RITZ-4)
CM O'Connor et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2003)
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease - Results from the AASK trial
JT Wright et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
Entry-into-humans study with tezosentan, an intravenous dual endothelin receptor antagonist
J Dingemanse et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2002)
Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: Safety and pharmacokinetics
MA Carducci et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Pharmacokinetics and pharmacodynamics of tezosentan, an intravenous dual endothelin receptor antagonist, following chronic infusion in healthy subjects
J Dingemanse et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2002)
Hyperhexosemia induced functional and structural changes in the kidneys: Role of endothelins
S Chen et al.
NEPHRON (2002)
Coronary vasodilation and improvement in endothelial dysfunction with endothelin ETA receptor blockade
JPJ Halcox et al.
CIRCULATION RESEARCH (2001)
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
BM Brenner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
EJ Lewis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Coexpression of endothelin-converting enzyme-1 and endothelin-1 in different stages of human atherosclerosis
C Ihling et al.
CIRCULATION (2001)
Effects of endothelin receptor antagonists on the progression of diabetic nephropathy
B Hocher et al.
NEPHRON (2001)
Share Paper
